Botanical species · safety record

Artemisia campestris

The EFSA Compendium of Botanicals holds 18 constituent measurements for Artemisia campestris. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Artemisia campestris L.

18Constituent measurements
0Safety records
11Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Myrcene5
  • Artemisinin4
  • 1,8-cineole3
  • Camphor2
  • Alpha-cedrol1
  • Dihydrocarvone1
  • Epoxides1
  • Proanthocyanidins (condensed tannins)1

Plant parts

  • Aerial part of plants11
  • Leaves4
  • Bud1
  • Flower1
  • Live plants1

Preparations

  • Essential oil13
  • Solvent extraction5

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
1,8-cineoleAerial part of plantsEssential oil19.2 PercentGC-MSResolve DOI
1,8-cineoleAerial part of plantsEssential oil2.6 PercentGC-MSResolve DOI
Alpha-cedrolAerial part of plantsEssential oil5.4 PercentGC-MSResolve DOI
ArtemisininBudSolvent extraction0.9 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ArtemisininFlowerSolvent extraction0.8 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ArtemisininLeavesSolvent extraction0.4 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
CamphorAerial part of plantsEssential oil2.7 PercentGC-MSResolve DOI
DihydrocarvoneAerial part of plantsEssential oil2.9 PercentGC-MSResolve DOI
MyrceneAerial part of plantsEssential oil3.3 PercentGC-MSResolve DOI
Proanthocyanidins (condensed tannins)Aerial part of plantsSolvent extraction114.3 Gram/kilogramUnspecifiedResolve DOI
1,8-cineoleAerial part of plantsEssential oil7.8 PercentNo resolvable identifier
ArtemisininAerial part of plantsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
CamphorAerial part of plantsEssential oil9.2 PercentGC-MSNo resolvable identifier
EpoxidesAerial part of plantsEssential oil≤ 8.1 PercentNo resolvable identifier
MyrceneLive plantsEssential oil1 PercentUnspecifiedNo resolvable identifier
MyrceneLeavesEssential oil≤ 4.3 PercentNo resolvable identifier
MyrceneLeavesEssential oil4.1 PercentGC-MSNo resolvable identifier
MyrceneLeavesEssential oil≥ 1.2 PercentNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Boufennara, S., Lopez, S., Bousseboua, H., Bodas, R., Bouazza, L. Chemical composition and digestibility of some browse plant species collected from Algerian arid rangelands . Spanish journal of agricultural research, 2012, vol. 10, no. 1, p. 88-98. DOI
  2. Silva, AMS., Seca, AML., Vasconcelos, JMJ., Cavaleiro, JAS., Silvestre, AJD., Domingues, FMJ., Neto, CP., Rauter, AP., Palma, FB., Justino, J., Araujo, ME., PinaDosSantos, S. Chemical composition of Artemisia campestris and Hibiscus cannabinus. Natural products in the new millennium: prospects and industrial application, 2002, vol. 47, p. 47-57.
  3. Akrout, A., Chemli, R., Simmonds, M., Kite, G., Hammami, M., Chreif, I. Seasonal variation of the essential oil of Artemisia campestris L.. Journal of essential oil research, 2003, vol. 15, no. 5, p. 333-336.
  4. Ranjbar, M., Naghavi, M.R., Alizadeh, H., Soltanloo, H. Expression of artemisinin biosynthesis genes in eight Artemisia species at three developmental stages. Industrial crops and products, 2015, vol. 76, p. 836-843. DOI
  5. Aicha, Neffati., Ines, Skandrani., Mohamed, Ben Sghaier., Ines, Bouhlel., Soumaya, Kilani., Kamel, Ghedira., Mohamed, Neffati., Imed, Chraief., Mohamed, Hammami., Leila, Chekir-Ghedira. Chemical composition, mutagenic and antimutagenic activities of essential oils from (Tunisian) Artemisia campestris and Artemisia herba-alba . Journal of essential oil research, 2008, vol. 20, no. 5, p. 471-477.
  6. Belhattab, R., Boudjouref, M., Barroso, J.G., Pedro, L.P., Figueirido, A.C. Essential oil composition from Artemisia campestris grown in Algeria. Advances in environmental biology, 2011, vol. 5, no. 2 SPEC. ISSUE, p. 429-432.
  7. Dob, T., Dahmane, D., Berramdane, T., Chelghoum, C. Chemical composition of the essential oil of Artemisia campestris L. from Algeria . Pharmaceutical biology, 2005, vol. 43, no. 6, p. 512-514. DOI
  8. Judzentiene, Asta., Budiene, Jurga., Butkiene, Rita., Kupcinskiene, Eugenija., Laffont-Schwob, Isabelle., Masotti, Veronique. Caryophyllene Oxide-rich Essential Oils of Lithuanian Artemisia campestris ssp. campestris and Their Toxicity . Natural product communications, 2010, vol. 5, no. 12, p. 1981-1984.
  9. Guven, Kasim Cemal. Turkish Artemisia species. II. Artemisia campestris.. Folia pharmaceutica (istanbul), 1963, vol. 5, p. 586-91.
  10. Erdemoglu, Nurgun., Orhan, Ilkay., Kartal, Murat., Adiguzel, Nezaket., Bani, Baris. Determination of artemisinin in selected Artemisia L. species of Turkey by reversed phase HPLC.. Records of natural products, 2007, vol. 1, no. 2-3, p. 36-43.
  11. Mucciarelli, M., Caramiello, R., Maffei, M., Chialva, P. Essential oils from some Artemisia species growing spontaneously in north-west Italy. Flavour and Fragrance Journal, 1995, vol. 10, no. 1, p. 25-32. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue